RT Journal Article SR Electronic T1 Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 560 OP 565 DO 10.1136/ijgc-2021-002999 VO 32 IS 4 A1 Paul A Cohen A1 Penelope M Webb A1 Madeleine King A1 Andreas Obermair A1 Val Gebski A1 Phyllis Butow A1 Rachael Morton A1 Wanda Lawson A1 Patsy Yates A1 Rachel Campbell A1 Tarek Meniawy A1 Michelle McMullen A1 Andrew Dean A1 Jeffrey Goh A1 Orla McNally A1 Linda Mileshkin A1 Philip Beale A1 Rhonda Beach A1 Jane Hill A1 Cyril Dixon A1 Sue Hegarty A1 Jim Codde A1 Angela Ives A1 Yeh Chen Lee A1 Alison Brand A1 Anne Mellon A1 Sanela Bilic A1 Isobel Black A1 Stephanie Jeffares A1 Michael Friedlander YR 2022 UL http://ijgc.bmj.com/content/32/4/560.abstract AB Background Physical symptoms, anxiety, depression, fear of recurrence, sexual dysfunction, and social withdrawal are common in women after treatment for ovarian cancer. Most patients would like and need help dealing with these symptoms. The traditional model of follow-up care is unstructured and largely focused on diagnosing recurrent disease, and most oncologists lack skills to identify and manage psychosocial issues. No high quality prospective clinical trials have been conducted to determine the optimal follow-up regimen or the cost effectiveness of ovarian cancer surveillance strategies.Primary Objective(s) To assess emotional wellbeing, acceptability, safety, and cost effectiveness of nurse led follow-up via telehealth for women with ovarian cancer following completion of primary treatment.Study Hypothesis We hypothesize that compared with routine clinic based follow-up, nurse led follow-up via telehealth, including serum CA125 monitoring and completion of a patient reported outcome instrument, the Measure of Ovarian Symptoms and Treatment concerns-Surveillance (MOST-S26), will improve emotional wellbeing in women with ovarian cancer; be feasible, safe, acceptable, and not delay the time to diagnosis of recurrent disease; will result in greater patient satisfaction; will identify more patients with psychological distress, lead to better care, and improved psychological outcomes; and be cost-effective.Trial Design Phase II multicenter randomized trial comparing 3 monthly nurse led telehealth consultations that include serum CA125 monitoring and completion of the MOST-S26, with routine clinic based follow-up. The allocation ratio will be 1:1.Major Inclusion/Exclusion Criteria Eligible patients will be women with high grade epithelial ovarian cancer who have normalized serum CA125 (to <35 kU/L) at completion of first line chemotherapy.Primary Endpoint(s) Emotional wellbeing at 12 months.Sample Size 150 patients.Estimated Dates for Completing Accrual and Presenting Results July 2023. Results expected in 2025, 24 months after the last participant is enrolled.Trial Registration ACTRN12620000332921There are no data in this work.